Securities attorney, Lars Soreide, of Soreide Law Group, PLLC, is currently investigating the Dendreon Corp. (NASDAQ: DNDN) for possible violations of federal securities laws after the company’s withdrawal of its sales forecasts for its prostate cancer therapy Provenge. Dendreon projected that it would earn between $350 - $400 million on sales of Provenge.
The Dendreon Corporation is a Seattle-based biotechnology company focused on the discovery, development and commercialization of novel therapeutics that may improve cancer treatment options for patients.
With the announcement of Dendreon withdrawing it's earnings guidance, the stock fell from a closing price on August 3, 2011 of $33.65 to an opening price on August 4, 2011 of $12.73. The shares of DNDN fell more than 60 percent after the company withdrew its 2011 revenue estimates allegedly costing the company $3.2 billion in market value. Today, it is at $11.05.
If you or a family member invested in DNDN stock and suffered losses, call a Securities Arbitration Lawyer for a free consultation on how to potentially recover your losses. To speak with an attorney, call 888-760-6552, or visit www.securitieslawyer.com.
Soreide Law Group, PLLC., representing investors nationwide before FINRA the Financial Industry Regulatory Authority.